Professor Vickie Lee

Professor Vickie Lee is professor of practice (ophthalmology) at Imperial College London and specialises in the treatment of all orbital, lacrimal and eyelid conditions.

She is a leading specialist in orbital trauma and thyroid eye disease. She is the British Oculoplastic Surgery Society's national lead for thyroid eye disease (TED), authored the national guidelines for TED, and led the compilation of a national directory for thyroid eye services. She leads multidisciplinary TED services across three NHS hospitals that are internationally recognised.

Professor Lee is also the UK chief investigator and principal investigator for many clinical trials of novel treatments for thyroid eye disease. She has lectured and published extensively on TED and orbital trauma in major peer-reviewed journals. She has represented her specialty on committees at the Royal College of Ophthalmologists and other national and international societies and on NICE panels.

She maintains an extensive network of leading specialists from other medical and surgical disciplines to ensure her patients can access the best multidisciplinary care possible.

Professor Lee is part of a small group of lacrimal specialists highly experienced in performing endonasal dacryocystorhinostomy for tear duct obstruction.

Alongside her clinical work, Professor Lee is dedicated to education, both for medical students at Imperial College London and for the next generation of ophthalmologists. In addition to her professorship, she is a clinical teacher for the medical school. She and her colleagues also run a successful oculoplastic fellowship programme for the next generation of oculoplastic surgeons.

She has been invited to convene, chair and lecture at many national and international conferences on a variety of topics including thyroid eye disease, orbital and facial trauma, and cosmetic rejuvenation, and has published in textbooks and many leading peer-reviewed journals.

You may also wish to read:

• Leading the way in thyroid eye disease

• Faces of Ophthalmology: Dr Vickie Lee

50+ Peer Reviewed research publications

1. THRIVE: A Phase 3, Randomized, Double-Masked, Placebo-Controlled Study of Veligrotug for Active Thyroid Eye Disease. Ophthalmology. 2026 Jun 1:S0161-6420(26)00293-9.

2. Mild Thyroid Eye Disease-The Most Common yet the Least Studied Presentation of Thyroid Eye Disease. Thyroid. 2026 Aug;36(8):817-826.

3. Horizon Scanning from Panel :Discussions at the EUGOGO Global TED Forum 2025 London Eye Eye (Lond). 2026 Mar;40(4):441-442

4. Multidisciplinary management of thyroid eye disease (TED) in patients with latent tuberculosis or chronic hepatitis B Thyroid Res. 2026 Jan 29;19(1):6

5. Low risk of thyroid eye disease (TED) following radioiodine (RAI) therapy in a multidisciplinary setting: a retrospective cohort study. Thyroid research, 18(1), 41.

6. Predictive demographic and clinical features for the development of dysthyroid optic neuropathy in a multi-ethnic TED population: a retrospective cohort study. Thyroid Res 18, 37 (2025).

7. Radiological Activity Score (RAS)- MRI Characteristics in Dysthyroid Optic Neuropathy in a Multi-Ethnic Thyroid Eye Disease Population. Clin Endocrinol (Oxf). 2025 Sep;103(3):385-395.

8. "Real-Life" Utility of the Graves' Ophthalmopathy- Quality of Life in a Multidisciplinary Thyroid Eye Disease Service. Ophthalmic Plast Reconstr Surg. 2025 Nov-Dec 01;41(6):688-700.

9. Quantitative Orbital MRI in the assessment of Thyroid Eye Disease to develop a Radiological Activity Score? Insights Imaging. 2024 Aug 1;15(1):183.

10. The changing landscape of thyroid eye disease: current clinical advances and future outlook, Eye 2024.